2025-11794RuleWallet

FDA Creates a New Regulatory Category for a Brain-Infection Test

Published Date: 6/26/2025

Rule

Summary

The FDA is officially putting the herpes simplex virus test for brain infections into a safer, easier-to-manage category called Class II. This change means the test will have special rules to keep it safe and effective, helping patients get quicker access to this important tool without unnecessary red tape. The new classification is effective June 26, 2025, and could save time and money for makers and users of the test.

Analyzed Economic Effects

4 provisions identified: 3 benefits, 1 costs, 0 mixed.

Developers Must Meet Detailed Special Controls

If you develop this HSV CNS assay, you must provide detailed design verification and validation documentation, including device description (components, ancillary reagents, primer design), analytical performance data (limit of detection, reactivity, inclusivity, precision, reproducibility, interference, cross-reactivity, carryover, cross-contamination), reagent and sample stability recommendations, a clinical study comparing performance to two PCR methods followed by bidirectional sequencing, an end-user training program, quality assurance protocols, and software documentation.

HSV CNS Test Reclassified to Class II

If you make or sponsor this herpes simplex virus (HSV) nucleic acid test for central nervous system (CNS) infections, the FDA has classified it as Class II (special controls). This order is effective June 26, 2025, the device is subject to premarket notification under section 510(k), and the classification was applicable on March 21, 2014.

De Novo Classification Enables Future 510(k) Predicates

Because FDA used the De Novo process to classify this device into Class II, this device can serve as a predicate for future similar devices, allowing other sponsors to use the less burdensome 510(k) pathway instead of submitting a De Novo request or premarket approval application.

Labeling Must Explain Results and Warn on Negatives

If you use this HSV CNS test, the labeling must give a detailed explanation of how to interpret results and the acceptance criteria, and it must state that negative results do not preclude HSV-1 or HSV-2 infection and should not be used as the sole basis for treatment or other patient management decisions.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
6/26/2025
6/26/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register